<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029011</url>
  </required_header>
  <id_info>
    <org_study_id>DMED-2496-21</org_study_id>
    <nct_id>NCT05029011</nct_id>
  </id_info>
  <brief_title>Low-cost Sensor System for COVID-19 Patient Monitoring: Validation of MediByte VTS</brief_title>
  <official_title>Low-cost Sensor System for COVID-19 Patient Monitoring: Validation of MediByte VTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helen S. Driver, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Braebon Medical Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MediByte VTS is a low-cost, portable device that is being developed to take continuous&#xD;
      and real-time vital sign measurements of COVID-19 patients, both in the hospital and home&#xD;
      setting. This study is being undertaken to test the MediByte VTS and validate against&#xD;
      industry standards.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In response to the COVID-19 pandemic, the MediByte Vital Signs Monitor (VTS) has been&#xD;
      developed with funding from the National Research Council of Canada Industrial Research&#xD;
      Assistance Program through the federal government's Innovative Solutions Canada (ISC)&#xD;
      program. The VTS will measure peripheral capillary oxygen saturation (SpO2) and pulse via&#xD;
      photoplethysmography (PPG), temperature, blood pressure (BP), heart and respiration rates,&#xD;
      electrocardiogram (ECG), head position and movement over a continuous period. This monitor&#xD;
      can be used remotely, and importantly will be low-cost so it can be accessed widely. Data&#xD;
      from the VTS is transmitted wirelessly to a portable basestation which is a smartphone or&#xD;
      tablet device via a customized application. This study will test the VTS both within the&#xD;
      clinical environment and in the remote home environment to see how well it monitors patients&#xD;
      effected by COVID-19 needing care, as well as satisfying an unmet need for remote monitoring&#xD;
      across the healthcare system.&#xD;
&#xD;
      This study will compare the newly developed VTS with an industry gold standard of&#xD;
      polysomnography (PSG) in the sleep laboratory, or in the home with the MediByte Jr (home&#xD;
      sleep apnea test).&#xD;
&#xD;
      Approximately 150 patients will be recruited to the study across two different settings which&#xD;
      includes a hospital setting and a remote setting, within the home environment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oximetry</measure>
    <time_frame>24 hours</time_frame>
    <description>Time spent with oxygen saturation &gt;=90%, time spent with oxygen saturation &lt;= 88%, number of desaturations of &gt;3%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Rate (heart rate/pulse)</measure>
    <time_frame>24 hours</time_frame>
    <description>range</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure (BP)</measure>
    <time_frame>evening and morning, in a 24 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature (forehead)</measure>
    <time_frame>evening and morning, in a 24 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body position (PSG and MediByte Jr) and head position (VTS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Time supine, lateral and prone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>range, in a 24 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of artifact</measure>
    <time_frame>24 hours</time_frame>
    <description>e.g. movement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Develop guidelines for the VTS</measure>
    <time_frame>Within 6 months</time_frame>
    <description>After assessing the usability of the VTS in the sleep laboratory and remote use in the home.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>The Focus is How Well the MediByte VTS Will Monitor Vital Signs</condition>
  <arm_group>
    <arm_group_label>Patients of the Sleep Disorders Laboratory</arm_group_label>
    <description>Monitoring vital signs</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MediByte VTS</intervention_name>
    <description>The MediByte VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the MediByte VTS for 24 hours.</description>
    <arm_group_label>Patients of the Sleep Disorders Laboratory</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of who under the care of the sleep disorders lab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients requiring a sleep evaluation using polysomnography&#xD;
&#xD;
          -  People referred to the sleep clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those unable and/or unwilling to consent&#xD;
&#xD;
          -  People who do not have access to home WIFI (applicable to participants local to&#xD;
             Kingston undertaking the study in the home setting)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Driver, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University and Kingston Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Driver, Phd</last_name>
    <phone>613-548-2300</phone>
    <email>helen.driver@kingstonhsc.ca</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Helen S. Driver, PhD</investigator_full_name>
    <investigator_title>Dr. Helen S. Driver, Assistant Professor, Division of Respirology and Sleep Medicine, Dept. Medicine, Queen's University</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

